Bone density loss after menopause: clinical prevention strategies

A fracture of the hip, vertebra, or wrist may be the first sign that bone strength has fallen, with consequences for mobility and independence.

The clinical question is how to identify women at meaningful fracture risk, what to measure, and when the benefits of treatment outweigh its risks. Prevention starts with understanding the pace of bone change, then matching screening and treatment to the individual rather than treating every postmenopausal woman as though she has the same risk.

The physiology of estrogen deficiency and bone turnover

Bone is living tissue, continually broken down and rebuilt. Osteoclasts resorb old bone; osteoblasts form new bone. Estrogen helps keep these processes in balance. It restrains osteoclast activity and supports osteoblast survival, while also influencing RANKL and osteoprotegerin, proteins involved in regulating bone resorption.

As estrogen levels fall during the menopause transition, that restraint weakens. Bone resorption increases, while new bone formation does not keep pace. The effect is especially important in trabecular bone, which is abundant in the vertebrae and parts of the hip. Bone mineral density (BMD) can decline, and the internal structure of bone can become less robust. A T-score captures density, but it does not describe every aspect of bone quality.

That distinction matters in practice. Two women with similar T-scores may have different fracture risks because of age, prior fractures, medication use, falls, or underlying conditions. A scan is an important part of assessment, but it is not a complete account of skeletal health.

The menopause transition is a period of accelerated change, not a guarantee that every woman will develop osteoporosis. Risk depends on the bone density a woman brings into menopause as well as factors such as genetics, body weight, smoking, alcohol use, physical activity, and certain medicines. Glucocorticoids, for example, can contribute to bone loss. So can conditions that affect absorption or hormone levels.

Lifestyle measures support bone health, but they have limits. Exercise, adequate nutrition, and avoiding smoking are valuable throughout adulthood. For women at high fracture risk, though, they cannot replace medication when medication is indicated.

DEXA screening protocols and fracture risk assessment

Dual-energy X-ray absorptiometry, usually called DEXA or DXA, is the standard test for measuring BMD. It commonly assesses the hip and lumbar spine. Results are reported as T-scores, which compare a person’s BMD with that of a healthy young adult reference population:

• Normal: T-score of −1.0 or higher
• Osteopenia: T-score below −1.0 but above −2.5
• Osteoporosis: T-score of −2.5 or lower

These categories are useful, but they should not be mistaken for a full treatment decision. A woman with a prior fragility fracture may need treatment even if her T-score does not fall into the osteoporosis range. Conversely, a low T-score needs to be interpreted alongside her age, health history, and likelihood of falling.

Routine screening is recommended for postmenopausal women aged 65 and older. For younger postmenopausal women, screening is considered when risk factors suggest an elevated likelihood of fracture. These may include low body weight, a parental history of hip fracture, smoking, excess alcohol, long-term glucocorticoid use, or a condition associated with bone loss.

Tools such as FRAX estimate 10-year fracture probability using clinical risk factors, with or without BMD. They help put a scan into context, but they are not substitutes for clinical judgment. A prior fracture, a rapidly changing medical picture, or a medication that affects bone may alter the decision even when a calculated score appears reassuring.

Repeat scanning should answer a clinical question. The interval depends on the initial result, the patient’s risk profile, and whether treatment has begun or changed. Repeating DEXA too soon may not show a meaningful change; waiting too long may be unhelpful when risk is high. The clinician should consider whether a new result could change management, and whether the same equipment and comparable measurement sites are being used where possible.

A T-score is a measurement at one point in time. The useful question is what it means alongside fracture history, age, and the direction of change.

Nutritional foundations: calcium and vitamin D

Calcium and vitamin D support bone mineralization, but taking more is not automatically better. The aim is to meet daily needs, preferably through food where practical, and to address a documented shortfall rather than treating supplements as a stand-alone osteoporosis strategy.

For women up to age 50, the recommended daily calcium intake is 1,000 mg. For women over 50, it is 1,200 mg. Dietary sources include dairy products, calcium-fortified foods, and some leafy greens. When intake is low, a supplement can help close the gap. Large supplemental doses may cause problems, including constipation or kidney stones in some people, so total intake from food and supplements should be considered together.

Vitamin D helps the body absorb calcium. Recommended daily intake is 600 IU through age 70 and 800 IU after age 70. Sun exposure, diet, supplements, and individual health all affect vitamin D status. Testing may be appropriate when deficiency is suspected or when a medical condition affects absorption or metabolism. Supplement dose should be tailored to the clinical situation rather than escalated without a reason.

The combination of calcium and vitamin D is often discussed as though it were a complete preventive treatment. It is not. These nutrients provide the materials needed for bone maintenance, but they do not reliably stop estrogen-related bone resorption or replace osteoporosis medication in someone at elevated fracture risk.

Calcium and vitamin D support bone health. They do not, by themselves, treat osteoporosis or remove the need to assess fracture risk.

Hormone replacement therapy as a preventive intervention

Hormone therapy can prevent bone loss and reduce fracture risk while it is being used. Its effect on bone is one part of a broader decision that should account for menopause symptoms, age, time since menopause, medical history, and personal preferences. It is not appropriate to prescribe systemic hormone therapy solely by looking at a T-score.

For healthy women who are younger than 60 or within 10 years of menopause onset, the benefit-risk balance is generally more favorable than it is for women starting therapy later. It may be especially relevant when menopause occurs early or when ovarian insufficiency leads to prolonged estrogen deficiency. In those circumstances, treatment decisions should take into account both symptoms and the consequences of years without estrogen.

Systemic hormone therapy is not suitable for everyone. A history of certain estrogen-sensitive cancers, unexplained vaginal bleeding, active liver disease, venous thromboembolism, or coronary heart disease may rule it out or require specialist assessment. The type of therapy also matters. A woman with a uterus generally needs progestogen alongside systemic estrogen to protect the endometrium; the route and formulation should be individualized.

For women beginning treatment at an older age or farther from menopause, the balance changes. Risks such as blood clots and stroke become more important, while other therapies can address fracture risk without using systemic estrogen. Hormone therapy should therefore be reviewed periodically, with attention to whether it is still needed for its original purpose and whether the patient’s risk profile has changed.

Pharmacotherapy pathways: bisphosphonates and anabolic agents

Medication is considered when fracture risk is high, including in women with osteoporosis-range BMD or a history of fragility fracture. The choice depends on the severity of risk, previous treatment, other medical conditions, and whether the patient can take the medicine as directed.

Bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid reduce osteoclast activity and slow bone resorption. Their fracture evidence is not identical. Alendronate, risedronate, and zoledronic acid have evidence for reducing hip fractures as well as vertebral fractures. Ibandronate reduces vertebral fracture risk, but has not been shown to reduce hip-fracture risk. That difference matters when the patient’s risk of a hip fracture is a central concern.

Bisphosphonates are often used as initial therapy for women at high fracture risk. The route varies: some are taken by mouth, while zoledronic acid is given intravenously. Oral medicines have specific administration requirements and may not suit people with certain esophageal or gastrointestinal conditions. Treatment is commonly reassessed after several years. For some patients, a temporary pause may be considered; for others, continuing treatment or choosing another therapy is more appropriate. Rare risks such as atypical femoral fracture and osteonecrosis of the jaw are part of that review, not a reason to avoid effective treatment automatically.

Denosumab blocks RANKL, a signal involved in osteoclast formation and activity. It can increase BMD and reduce fracture risk, but it should not be stopped without a plan. Bone turnover can rise quickly after discontinuation, with rapid bone loss and an increased risk of vertebral fractures. A clinician should arrange follow-on antiresorptive treatment if denosumab is being discontinued.

Romosozumab acts on sclerostin and has both bone-forming and antiresorptive effects. It may be considered for women with severe osteoporosis or very high fracture risk when a rapid increase in BMD is needed. Treatment is limited to a defined course, after which another osteoporosis medicine is generally used to maintain gains. It carries a warning about possible cardiovascular harm, so a history of myocardial infarction or stroke and the patient’s overall cardiovascular risk need careful consideration.

Medication works best as part of a broader approach to fracture prevention. Weight-bearing activity and resistance exercise help preserve strength and function. Balance training and fall-prevention measures can reduce the chance that fragile bones are exposed to a fall. Smoking cessation and moderation of alcohol are also relevant. These steps are not a substitute for pharmacotherapy in a woman at high risk, but they can address risks that a prescription alone cannot.

A clinical decision, revisited over time

Postmenopausal bone loss is common, but fracture risk is not uniform. The prevention plan should bring together DEXA findings, prior fractures, FRAX estimates, nutrition, medications, falls, and the patient’s broader health. If treatment begins, follow-up should assess whether it is tolerated, whether doses are being taken correctly, and whether the plan still fits the person’s changing circumstances.

The practical task is to intervene at the level of risk. Adequate calcium and vitamin D support the foundation; activity and fall prevention protect function; hormone therapy may be appropriate for some women in the right clinical window; and osteoporosis medicines are available when fracture risk warrants them. A good plan is specific, revisited, and grounded in evidence rather than in promises of a single supplement or universal solution.